PRMT5 Related Tumor Models

Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as glioblastoma represents a potentially targetable vulnerability. MTAP deletions occur in approximately 10 – 15% of all human cancers. When the MTAP gene is deleted, methylthioadenosine (MTA) accumulates and selectively inhibits PRMT5. This creates a synthetic lethal dependence on PRMT5 in MTAP-deleted tumors.

As a potential treatment for MTAP-deleted cancers, compound MRTX1719 is a PRMT5 inhibitor that selectively binds to the PRMT5-MTA complex and inhibits PRMT5 activity in MTAP-deleted cells. To support the discovery and optimization of new PRMT5 inhibitors, WuXi AppTec has established an extensive panel of PRMT5 related CDX and PDX models.

PRMT5 Related Tumor Models

Download